Trials / Completed
CompletedNCT05586516
A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer
A Phase 1b, Open Label, Dose Escalation Study of IOA-289, an Orally Bioavailable, Selective Autotaxin (ENPP2) Inhibitor Alone and in Combination With Gemcitabine/Nab-paclitaxel in Patients With Metastatic Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- iOnctura · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of study IOA-289-102 is to evaluate the safety and tolerability of escalating doses of IOA-289 in patients with metastatic pancreatic cancer in combination with standard chemotherapy consisting of gemcitabine and nab-paclitaxel. Blood and tumour samples for PK and PD will be collected and assessments for determination of any clinical efficacy will be completed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IOA-289 | IOA-289 will be administered orally twice daily (BID), starting from C0D1. Gemcitabine and nab-paclitaxel will be administrated by IV infusion, weekly for 3 weeks of a 4 week cycle starting at C1D1. |
Timeline
- Start date
- 2022-10-10
- Primary completion
- 2025-08-18
- Completion
- 2025-08-18
- First posted
- 2022-10-19
- Last updated
- 2026-03-30
Locations
3 sites across 2 countries: Italy, United Kingdom
Source: ClinicalTrials.gov record NCT05586516. Inclusion in this directory is not an endorsement.